Get startedLog in
    Picture of Opus Genetics logo

    IRD — Opus Genetics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousSmall CapMomentum Trap
    All News

    Brief: Ocuphire Pharma Says It Initiates Vega-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% For Presbyopia

    Picture of Opus Genetics logoOpus Genetics
    06/09/2024 01:46
    Sept 5 (Reuters) - Ocuphire Pharma Inc  OCUP.O :
    * UPDATE – OCUPHIRE PHARMA INITIATES VEGA-3 PHASE 3 TRIAL
EVALUATING PHENTOLAMINE OPHTHALMIC SOLUTION 0.75% FOR PRESBYOPIA
    * OCUPHIRE PHARMA INC - TOP-LINE DATA FROM VEGA-3 PHASE 3
TRIAL
EXPECTED H1 2025
    * OCUPHIRE PHARMA INC - TOP-LINE DATA FROM LYNX-2 PHASE 3
TRIAL
EXPECTED Q1 2025

Source text for Eikon:  ID:nGNX2ft9QX 
Further company coverage:  OCUP.O 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Opus Genetics

    See all news